Aerie Pharmaceuticals — Investor Presentation (April 2020)
28 slides from Aerie Pharmaceuticals's investor presentation, Apr 14, 2020

Slide 1: Company Overview Investor Presentation April 2020
Company Overview Investor Presentation April 2020 Exhibit 99.1

Slide 2: Important Information
For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

Slide 3: Aerie Overview
Aerie Overview Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indicat

Slide 4: 2019 U.S. Glaucoma Market
Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

Slide 5: Rocklatan Phase 3 Month 12 Responder Analysis
For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

Slide 6: Topline Results from Rhopressa Phase 4 Multi-center Open-label Study (MOST)
Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

Slide 7: U.S. Glaucoma Franchise Launch Update
For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 4/10/2020 IQVIA Weekl

Slide 8: U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week
U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week For Investor Use Source: IQVIA Rhopressa® bottles per Rx for year-to-date week ending 4/3/2020 were 1.37 compared to March Quarter 2019 of 1.27, reflecting an increase in 90 days’ supply. TRx % Change Versus Prior Week NRx % Change Versus P

Slide 9: TRx Growth By Branded Product
TRx Growth By Branded Product For Investor Use Product Dec ‘19 TRx Change from Dec ‘18 Aerie Franchise 45,798 24,506 Vyzulta® 13,796 5,752 Combigan® 159,299 2,877 Zioptan® 12,298 130 Lumigan® 201,668 137 Simbrinza® 42,666 (826) Cosopt PF® 5,268 (3,875) Alphagan® P 82,949 (4,365) Azopt® 43,486 (9,362

Slide 10: Aerie & COVID-19: U.S. Sales Activities
Aerie & COVID-19: U.S. Sales Activities Sales: Utilizing a new sales tool kit with a digital focus Sales reps communicating with physicians using virtual detailing platforms (such as Zoom) and email Weekly email blasts and increasing video content Webinars for physicians (replacing local speaker mee

Slide 11: 84% of OPH offices are currently open
84% of OPH offices are currently open while a variety of mechanisms are being deployed For Investor Use Source: Market Research

Slide 12: Aerie & COVID-19: Ex-U.S. Activities & Pipeline
Aerie & COVID-19: Ex-U.S. Activities & Pipeline Ex-U.S. Activities Europe: Mercury 3 readout potentially by late 2020 Japan: PMDA meeting scheduled for Q2 2020 Pipeline AR-1105: Enrollment complete; readout for H2 20 remains on track AR-13503: Minimum enrollment complete, study remains on track to b

Slide 13: Market Access as of April 2020
For Investor Use Market Access as of April 2020 Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 75% of covered lives, increasing to 88% May 1, 2020 Rocklatan® Commercial ~ 88% of co

Slide 14: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

Slide 15: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQVIA unit data (1 month = 1 TRx) Aer

Slide 16: AR-13324-CS208 Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

Slide 17: Advancing the Pipeline
For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

Slide 18: U.S. Dry Eye Market
For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates – Feb 2020 US 2019 Sales: $1.6B est.

Slide 19: AVX-012 (now named AR-15512) for Dry Eye
For Investor Use AVX-012 (now named AR-15512) for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) T

Slide 20: AR-15512 (TRPM8 Agonist) for Dry Eye
AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

Slide 21: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights
AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score

Slide 22: Bringing Small Molecule Therapy to Back of the Eye
Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic

Slide 23: Aerie's Ophthalmic Implant Platform
For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi

Slide 24: 2019 U.S. Retinal Disease Market
For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

Slide 25: Aerie's Sustained Implant Opportunities
For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)

Slide 26: Aerie's Lead Implant Product Candidates
For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr

Slide 27: Aerie's Key Catalysts for 2020
Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 stage 2 clinical study expected to commence H2 2020 Globalization: Roclanda® Mercury 3 topline readou

Slide 28: Summary
For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Avizorex TRPM8 agonist for dry eye Retina Program Well-Financ
Source: SEC EDGAR · 8-K filed Apr 14, 2020
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
Investor Presentation (January 2022)33 slides · Jan 5, 2022